Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|October 5, 2026

The BioPharm Brief: Obesity Data and Manufacturing Shape Drug Progress

Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, clinical progress, and regulatory strategy. Today’s update focuses on new obesity data, expanded biosimilar manufacturing capacity, a manufacturing-related FDA review delay, and longer-term results for a potential cutaneous lupus treatment.

An investigational dual agonist is showing progress in the increasingly competitive obesity and metabolic disease field. Survodutide met both co-primary endpoints in the phase 3 SYNCHRONIZE-2 trial in adults with overweight or obesity and type 2 diabetes. At 76 weeks, weight loss reached up to 13.1% under the efficacy estimand, compared with 3.1% for placebo, while hemoglobin A1C fell by as much as 1.21 percentage points. However, gastrointestinal adverse events led 18% of treated participants to discontinue therapy, an important consideration as developers compete in the incretin market.

Turning to manufacturing, FDA has approved Alvotech’s second production suite in Reykjavik, Iceland, for commercial US supply of SIMLANDI, its adalimumab biosimilar. The approval allows drug substance manufacturing in either of the company’s 2 suites and doubles the manufacturing capacity available for US supply. It also follows resolution of FDA inspection-related matters at the facility, highlighting the regulatory importance of manufacturing readiness alongside biosimilar development.

That manufacturing theme carries into the next story, in which FDA extended its review of Novo Nordisk’s denecimig for hemophilia A because of ongoing remediation at a manufacturing facility. The agency has not identified deficiencies involving the therapy’s clinical efficacy or safety data, according to the company. Novo continues working with FDA and is targeting a potential US launch in the first half of 2027.

Finally, longer-term data for litifilimab show continued skin improvements through 52 weeks in the AMETHYST study of cutaneous lupus erythematosus. Phase 3 results are expected in the first half of 2027.

Thanks for listening to The BioPharm Brief. For more analysis and expert insights, please visit www.BioPharmInternational.com.

Key takeaways

  • Survodutide combines weight-loss and glycemic-control effects in type 2 diabetes, though tolerability remains important.
  • Manufacturing capacity and facility remediation continue to influence regulatory timelines.
  • Litifilimab shows durable skin responses in a disease with limited targeted treatment options.

Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.